Eli Lilly Acquires SiteOne Therapeutics to Develop Non-Opioid Pain Treatment STC-004

Eli Lilly and Company has announced its acquisition of SiteOne Therapeutics, a move aimed at advancing non-opioid pain treatments and expanding its pipeline for pain therapies. The deal includes the development of STC-004, a promising investigational therapy targeting chronic pain. This acquisition aligns with Eli Lilly’s broader strategy to address unmet needs in pain management through innovative approaches that do not rely on opioids.

The transaction is expected to bolster Eli Lilly’s efforts in creating next-generation treatments for pain conditions. STC-004, the centerpiece of this acquisition, is designed to provide relief for chronic pain sufferers without the risks associated with opioid-based medications. By integrating SiteOne Therapeutics’ expertise and resources into its operations, Eli Lilly aims to accelerate research and development in this area. The company has expressed its commitment to addressing the growing demand for safer and more effective pain management solutions.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: May 28, 2025

Related posts:

DrugPatentWatch Analysis: Biopharma FTO Improved with Machine Learning and Human Expertise Combination Uncertainty Drives Focus on Flexible Supply Chain Investments Says Logility VP New Marker Identified to Enhance Selection of Stem Cell-Derived Islets for Diabetes Treatment Microbial Fermentation Gains Traction as CMOs Dominate Biologics Production Capacity

Author

Mark Chiang